RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target

Research output: Contribution to journalReview articlepeer-review

Abstract

Since its discovery, alternative splicing has been recognized as a powerful way for a cell to amplify the genetic information and for a living organism to adapt, evolve, and survive. We now know that a very high number of genes are regulated by alternative splicing and that alterations of splicing have been observed in different types of human diseases, including cancer. Here, we review the accumulating knowledge that links the regulation of alternative splicing to the response to chemotherapy, focusing our attention on ovarian cancer and platinum-based treatments. Moreover, we discuss how expanding information could be exploited to identify new possible biomarkers of platinum response, to better select patients, and/or to design new therapies able to overcome platinum resistance.

Original languageEnglish
Pages (from-to)586-615
Number of pages30
JournalMedicinal Research Reviews
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 2021

Keywords

  • alternative splicing
  • clinical trials
  • DNA repair
  • drug uptake and detoxification
  • ovarian cancer
  • peritoneal dissemination
  • platinum chemotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target'. Together they form a unique fingerprint.

Cite this